Blog
About

2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Factors Associated With Guideline-recommended KRAS Testing in Colorectal Cancer Patients: A Population-based Study.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Response to epidermal growth factor receptor inhibitors is poorer among stage IV colorectal cancer (CRC) patients with KRAS mutations; thus KRAS testing is recommended before treatment. KRAS testing was collected by Surveillance, Epidemiology, and End Results (SEER) registries for 2010 CRC cases, and our goal was to provide the first population-based estimates of testing in the United States.

          Related collections

          Author and article information

          Journal
          Am. J. Clin. Oncol.
          American journal of clinical oncology
          Ovid Technologies (Wolters Kluwer Health)
          1537-453X
          0277-3732
          Oct 2017
          : 40
          : 5
          Affiliations
          [1 ] *Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA †Division of Gastroenterology, School of Medicine, Tulane University ‡Louisiana Tumor Registry and Epidemiology Program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA.
          NIHMS669043
          10.1097/COC.0000000000000191
          4591083
          25844824

          Comments

          Comment on this article